<DOC>
	<DOCNO>NCT02533960</DOCNO>
	<brief_summary>The Registry Acute Stroke Under Novel Oral Anticoagulants-Prime ( RASUNOA-Prime ) , investigator-initiated study , German multicenter , prospective , observational registry . It perform 50 certified stroke-units support unrestricted grant different pharmaceutical company Heidelberg University Hospital . RASUNOA-Prime design assess emergency management acute ischemic hemorrhagic stroke patient atrial fibrillation ( AF ) different anticoagulation scheme pre stroke : Non-vitamin K antagonist oral anticoagulant ( NOAC ) , Vitamin K antagonist ( VKA ) , anticoagulation .</brief_summary>
	<brief_title>Registry Acute Stroke Under Novel Oral Anticoagulants - Prime</brief_title>
	<detailed_description>The main purpose observational cohort study assess routine emergency management acute stroke patient AF different anticoagulation scheme index stroke . The investigator address follow aims objective : 1 . Describing emergency management stroke patient ( IS ICH ) AF clinical routine include early diagnostic , therapeutic preventive procedure assess variation emergency management patient AF anticoagulation scheme pre stroke . 2 . Identifying variation risk early complication ( e.g . symptomatic secondary intracerebral haemorrhage ischemic stroke patient ) AF different anticoagulation scheme pre stroke . 3 . Determining factor influence outcome stroke patient AF three month clarify potential influence different anticoagulation scheme pre stroke . The registry consist 2 separate substudies cover two different patient cohort : ischemic stroke intracerebral hemorrhage . The study collect information prospectively enrol Neurology department certify stroke unit across Germany . The principal investigator , Prof. Dr. med . Roland Veltkamp , affiliate Imperial College London , UK , Heidelberg University Hospital , Germany .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Ischemic stroke substudy : Age &gt; = 18 year Informed consent Acute ischemic stroke either symptom last â‰¥ 24h evidence infarction brain image Anticoagulation NOAC Anticoagulation VKA No anticoagulation Previous/present atrial fibrillation No inform consent Symptomonset &gt; 24 h Hemorrhagic stroke substudy : Age &gt; = 18 year Acute primary intracerebral hemorrhage ) Anticoagulation NOAC b ) Anticoagulation VKA c ) No anticoagulation Previous/present atrial fibrillation No inform consent Symptomonset &gt; 24 h</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Registry Acute Stroke Under Novel Oral Anticoagulants</keyword>
</DOC>